API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Lead Product(s): Alisertib,Anastrozole
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of small cell lung cancer.
Lead Product(s): Alisertib
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
MLN8237 (alisertib) is a high affinity, selective, orally bioavailable inhibitors of Aurora A. It is being developed for the treatment of HER2-negative, HR-positive metastatic breast cancer.
Lead Product(s): Alisertib,Anastrozole
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
MLN8237 (alisertib), a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Lead Product(s): Alisertib
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
ALI-4201 (alisertib), a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
Lead Product(s): Alisertib
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
Alisertib (MLN8237), is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Lead Product(s): Alisertib
Therapeutic Area: Oncology Product Name: MLN8237
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Puma Biotechnology
Deal Size: $294.3 million Upfront Cash: $7.0 million
Deal Type: Licensing Agreement September 20, 2022